Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | CLK3 | P49761 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388496 | 0.85 | ADORA2A (0.58) | ADORA2AGSK3BCSNK1DLRRK2DYRK1A | |
| SCHEMBL13812153 | 0.84 | GSK3B (0.47) | GSK3BLRRK2CLK2CLK3DYRK1A | |
| SCHEMBL4080023 | 0.82 | CSNK1D (0.56) | ADORA2AGSK3BCSNK1DLRRK2CLK2 | |
| SCHEMBL5246773 | 0.82 | CSNK1D (0.68) | ADORA2AGSK3BCSNK1DLRRK2CLK2 | |
| SCHEMBL4085697 | 0.82 | CSNK1D (0.51) | ADORA2ACSNK1DLRRK2CLK2 | |
| SCHEMBL4090371 | 0.81 | CSNK1D (0.67) | ADORA2AGSK3BCSNK1DLRRK2CLK2 | |
| SCHEMBL4080101 | 0.81 | CSNK1D (0.52) | ADORA2ACSNK1DLRRK2 | |
| SCHEMBL4085531 | 0.81 | CLK2 (0.53) | ADORA2AGSK3BCSNK1DCLK2CLK3 | |
| SCHEMBL4080009 | 0.81 | CSNK1D (0.49) | ADORA2ACSNK1DLRRK2TTK | |
| SCHEMBL4080007 | 0.81 | CSNK1D (0.49) | ADORA2ACSNK1DLRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | ADORA2A 1535/4885GSK3B 8/4885CSNK1D 702/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | ADORA2A 1577/4885GSK3B 8/4885CSNK1D 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.